Press release from Companies
Publicerat: 2023-05-11 16:49:17
Oslo, Norway, May 11, 2023 - Genetic Analysis AS (the "Company", Ticker: GEAN) held its Annual General Meeting today, May 11th, at 15:00 hours (CET) on the Company's premises in Ulvenveien 80, Oslo. All items on the agenda were approved as proposed.
The agenda for the meeting was as follows: 1. Election of a chairperson and a person to co-sign the minutes 2. Approval of the annual accounts and directors' report of Genetic Analysis AS for 2022, including allocation of the result of the year 3. Remuneration to the Company's auditor 4. Election of members to the board of directors - Per Matsson – Chairperson 5. Remuneration of the board of directors Per Matsson – Chairperson; Camilla Huse Bondesson – Board member; Staffan Strömberg – Board member; Rune Sørum – Board member; 6. Election of the nomination committee 7. Remuneration to the Company's nomination committee Chair of the nomination committee: NOK 30.000 per year The decision was unanimously adopted. 8. Authorisation to the board of directors to increase the share capital The decision was unanimously adopted. 9. Authorisation to the board of directors to acquire own shares The decision was unanimously adopted. 10. Amendment of the Articles of Association The following text shall be included in the Company's articles of association by including a new provision (§ 11): § 11 When documents that relates to matters to be considered at the general meeting is made available for the shareholders at the company's websites, the board may determine that the documents shall not be distributed to shareholders. This also applies to documents that by law shall be included in or attached to the notice for the general meeting. A shareholder may still demand that the company sends such documents. The company may not require any compensation for sending documents to shareholders. The decision was unanimously adopted. For further information, please contact: About Genetic Analysis: For more information: www.genetic-analysis.com Interested in reading more about GA's products? Please visit ga-map.com
Chairperson Per Matsson was elected to chair the general meeting, and Eilert Aamodt was elected to co-sign the minutes with the chairperson.
The annual accounts and the director’s report for the Company for 2022 are approved, including the board of directors’ proposal for allocation of the result of the year.
Remuneration to the Company’s auditor for the accounting year of 2022 is approved in accordance with the information presented in the annual accounts for the Company for 2022.
The Company's existing board members are re-elected for the period until the next annual general meeting in the Company. The Company’s board of directors thus consist of:
- Andrew Stapleton – Board member
- Rune Sørum – Board member
- Camilla Huse Bondesson – Board Member
- Staffan Strömberg – Board member
The general meeting unanimously resolved the following board remuneration to apply in the period until the next ordinary general meeting:
Remuneration of NOK 400.000 per year
Remuneration of NOK 125.000 per year
Remuneration of NOK 125.000 per year
Remuneration of NOK 125.000 per year
In accordance with the proposal of the board of directors, the general meeting re-elected unanimously Kari Stenersen as Chair of the nomination committee. Svein Lien and Eilert Aamodt were elected as members.
In accordance with the proposal of the board of directors, the general meeting resolved the following board remuneration to apply in the period until the next ordinary general meeting:
Other members: NOK 15.000 per year
In accordance with the proposal of the board of directors the general meeting resolved as follows:
In accordance with the proposal of the board of directors the general meeting resolved as follows:
In accordance with the board’s proposal, the general meeting adopted the following resolution:
Eilert Aamodt, CFO
E-mail: ea@genetic-analysis.com
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.